ELI LILLY & CO (LLY) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:LLY - US5324571083 - Common Stock
LLY Key Statistics, Chart & Performance
The current stock price of LLY is 1061.46 USD. In the past month the price increased by 2.66%. In the past year, price increased by 30.21%.
LLY Latest News, Press Relases and Analysis
LLY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 19.79 | 495.04B | ||
| MRK | MERCK & CO. INC. | 12.38 | 270.66B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.30B | ||
| ZTS | ZOETIS INC | 20.37 | 56.91B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.87 | 23.42B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.58 | 11.72B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.59B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.60B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.38B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 17.33 | 4.09B |
Related stock screener links
About LLY
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA 46285 US
CEO: David A. Ricks
Employees: 47000
Phone: 13172762000
ELI LILLY & CO / LLY FAQ
Can you describe the business of ELI LILLY & CO?
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The firm is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). The company is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
What is the stock price of ELI LILLY & CO today?
The current stock price of LLY is 1061.46 USD. The price increased by 1.92% in the last trading session.
Does LLY stock pay dividends?
ELI LILLY & CO (LLY) has a dividend yield of 0.64%. The yearly dividend amount is currently 4.93.
What is the ChartMill rating of ELI LILLY & CO stock?
LLY has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
When is the next dividend date for ELI LILLY & CO (LLY)?
The next ex-dividend date for ELI LILLY & CO (LLY) is February 13, 2026.
Is ELI LILLY & CO (LLY) expected to grow?
The Revenue of ELI LILLY & CO (LLY) is expected to grow by 41.27% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns ELI LILLY & CO?
You can find the ownership structure of ELI LILLY & CO (LLY) on the Ownership tab.
LLY Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LLY. When comparing the yearly performance of all stocks, LLY is one of the better performing stocks in the market, outperforming 86.51% of all stocks.
LLY Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to LLY. LLY has an excellent profitability rating, but there are some minor concerns on its financial health.
LLY Financial Highlights
Over the last trailing twelve months LLY reported a non-GAAP Earnings per Share(EPS) of 21.99. The EPS increased by 116.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 30.99% | ||
| ROA | 16.02% | ||
| ROE | 77.38% | ||
| Debt/Equity | 1.72 |
LLY Forecast & Estimates
37 analysts have analysed LLY and the average price target is 1108.67 USD. This implies a price increase of 4.45% is expected in the next year compared to the current price of 1061.46.
For the next year, analysts expect an EPS growth of 84.97% and a revenue growth 41.27% for LLY